Destination

2025-03-11

Viking Therapeutics closer to bringing its Ozempic competitor to market

Viking Therapeutics (VKTX), the developer of a promising experimental weight-loss drug, has announced a multi-year partnership with CordenPharma, a leading contract manufacturing firm.

Read more...

[...]

Rating

Innovation

Pricing

Technology

Usability

We have discovered similar tools to what you are looking for. Check out our suggestions for similar AI tools.

blogspot

2024-11-08

Ahrefs vs SEMrush: Which SEO Tool Should You Use?

SEMrush and Ahrefs are among<br /> the most popular tools in the SEO industry. Both companies have been in<br /> business for years and have thousands of customers per month.<br /> & [...]

Match Score: 52.80

Destination

2025-03-07

Wegovy's price cut, Amgen's Ozempic competitor, and Big Pharma's tax cut: Pharma news roundup

Novo Nordisk just cut the price of its weight-loss drug, Wegovy, by more than half for patients who pay without insurance. Amgen (AMGN) announced this week that it has begun two late-stage clinical tr [...]

Match Score: 45.26

Destination

2025-02-18

Paperplane Therapeutics raises $1.5M to treat anxiety and pain with medical VR

Paperplane Therapeutics has raised $1.5 million to treat patients for pain and anxiety using virtual reality. [...]

Match Score: 42.54

thenextweb

2025-01-10

Verdiva launches with $410M for weight loss drugs to challenge Ozempic, Wegovy

London-headquartered biotech startup Verdiva has emerged from stealth with a whopping $410mn for a new range of drugs aimed at tackling the obesity epidemic. It’s one of Europe’s largest-ever biot [...]

Match Score: 41.25

Destination

2025-03-14

An Ozempic successor falls short, Eli Lilly's GLP-1 pill, and senators grill RFK: Pharma news roundup

An Eli Lilly exec said the company’s experimental weight-loss pill could make GLP-1 treatments more accessible worldwide, as it would be easier to manufacture and distribute globally. Three U.S. sen [...]

Match Score: 39.16

Destination

2025-03-10

Novo Nordisk's Ozempic successor disappointed Wall Street again

Novo Nordisk (NVO) released clinical trial results for its potential Ozempic successor on Monday, disappointing Wall Street for the second time.Read more... [...]

Match Score: 38.90

Destination

2025-04-01

Here's how much Ozempic and similar drugs have soared in popularity since 2018

The use of GLP-1 meds — made popular by Ozempic (NVO) — among U.S. adults without diabetes more than tripled between 2018 and 2022, with annual spending surging from $1.6 billion to $5.8 billion.R [...]

Match Score: 38.36

Destination

2025-05-16

Novo Nordisk's CEO is out after the Ozempic maker's stock dropped 50% in a year

Novo Nordisk (NVO) CEO Lars Fruergaard Jørgensen will step down after eight years at the helm of the Danish pharmaceutical giant responsible for the blockbuster drugs Ozempic and Wegovy, the company [...]

Match Score: 38.36

Destination

2025-04-14

Pfizer just had a big setback in its race for an Ozempic competitor

Pfizer (PFE) announced Monday that it is ending development of its daily weight-loss pill following a liver injury to a patient participating in a trial.Read more... [...]

Match Score: 35.67